Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

European News

New analysis shows maintained efficacy and safety of LIXIANA®▼ (edoxaban) in patients with acute VTE requiring a reduced dose based on clinical criteria

Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate

Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management

Daiichi Sankyo Provides Update on Her3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)

Daiichi Sankyo Partners With World Thrombosis Day

UK’s NICE recommends once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation

Target 70%: At ESC Congress 2015 Experts Discussed French, Italian and Austrian Initiatives for Better Blood Pressure Control

UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults

Real World ETNA Registries of New Once-Daily LIXIANA® (edoxaban) Start in Europe

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

Global News

Global LIXIANA® Press Portal

Cookie preferences tool